Updated: May 25
We are excited to announce that this week, we will be collaborating with Lantern Pharma for #BrainTumorAwarenessMonth in an effort to continue our mission of spreading awareness and information about ATRT.
We recently met Lantern at the American Association for Cancer Research (AACR) annual meeting where we learned about their commitment to supporting the ATRT cancer community and how they are using AI to help develop novel drugs for ATRT and other pediatric brain cancers. Learn more about Lantern by visiting their website LanternPharma.com or vising their social channels Lantern Pharma Inc | LinkedIn & @LanternPharma | Twitter
[Video] ATRT Facts
[Video] Drug Facts
Did you know – There have been NO drugs developed and approved specifically to treat malignant pediatric brain tumors like ATRT?
An urgent and unmet need is for the development of safe and effective cancer treatment options.
Lantern and their subsidiary Starlight Therapeutics are committed to shifting the narrative for drug development for pediatric brain tumor patients. One way they are doing this is by leveraging AI to help develop novel and effective therapies to help create meaningful change for these patients.
Zion's courageous battle gives us the drive to make a difference for the next child.
Today we are sharing the Angel story of Zion Yamoah, the son of Hope4ATRT Foundation founders, to honor his legacy and to support all the other incredible children who are fighting battles with ATRT.
His story reminds us of the challenges that ATRT patients face and the importance of our efforts to develop therapies to help fight this very rare and aggressive #braintumor.
Learn more about Zion’s story and the Yamoah family’s journey at: https://youtu.be/EVQt1drb7kQ